Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837994 | 0.87 | L3MBTL1 (0.65) | HTTKDM4EL3MBTL1SMN1; SMN2POLB | |
| SCHEMBL5362778 | 0.86 | HTT (0.71) | HTTKDM4EL3MBTL1SMN1; SMN2POLB | |
| SCHEMBL11214715 | 0.85 | L3MBTL1 (0.46) | HTTKDM4EL3MBTL1SMN1; SMN2POLB | |
| SCHEMBL7903525 | 0.85 | KDM4E (0.61) | HTTKDM4EL3MBTL1BCL2A1SMN1; SMN2 | |
| SCHEMBL15060188 | 0.85 | KDM4E (0.61) | HTTKDM4EL3MBTL1BCL2A1SMN1; SMN2 | |
| SCHEMBL6630373 | 0.83 | HTT (0.59) | HTTKDM4EL3MBTL1BCL2A1SMN1; SMN2 | |
| SCHEMBL2798208 | 0.83 | HTT (0.59) | HTTKDM4EL3MBTL1BCL2A1SMN1; SMN2 | |
| SCHEMBL3947553 | 0.81 | L3MBTL1 (0.63) | HTTKDM4EL3MBTL1BCL2A1SMN1; SMN2 | |
| SCHEMBL637156 | 0.80 | KDM4E (0.56) | HTTKDM4EL3MBTL1BCL2A1SMN1; SMN2 | |
| SCHEMBL22209067 | 0.80 | HTT (0.60) | HTTKDM4EL3MBTL1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934064-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-01-09 | — | — | EP | claimed |
| EP-0934064-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-08-11 | — | — | EP | claimed |
| WO-1998017274-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1998-04-30 | — | — | WO | claimed |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| WO-2010024430-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-03-04 | — | — | WO | disclosed |
| EP-0934064-B1 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2003-03-12 | — | — | EP | disclosed |
| US-4329454-A | Cephalosporin compounds | ELI LILLY AND COMPANY (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | PRKCZ, DCLK1, AAK1 | HTT 4880/4885KDM4E 1012/4885L3MBTL1 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.